NEW YORK (GenomeWeb) – Qiagen and NeoGenomics said on Friday that they have inked a master service agreement designed to expedite the development and launch of companion diagnostics with pharmaceutical partners.

Under the terms of the partnership, Qiagen will provide investigational-use-only tests to NeoGenomics and other labs "enabling them to verify, set up, and run our companion diagnostics in clinical trials and in anticipation of regulatory approval," Qiagen CEO Peer Schatz said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.